



Tocilizumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

| | |
|--------------------|---|
| INN | Tocilizumab |
| ATC codes | L04AC07 |
| Medicine type | Biological agent |
| EML status history | Application rejected in 2021 (TRS 1035) for Juvenile systemic arthritis |
| Wikipedia | Tocilizumab  |
| DrugBank | Tocilizumab  |

Recommendations

Section Medicines for juvenile joint diseases

Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

